<DOC>
	<DOCNO>NCT01344889</DOCNO>
	<brief_summary>This observational study ass factor lead dose reductions/treatment discontinuation effect sustain virological response patient chronic hepatitis C receive long-acting interferon ( e.g . Pegasys/peginterferon alfa-2a ) ribavirin . Data collect patient duration treatment 6 month thereafter .</brief_summary>
	<brief_title>An Observational Study The Prediction Adverse Events Patients With Chronic Hepatitis C Receiving Long-Acting Interferon Plus Ribavirin ( GUARD-C )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Adult patient ( accord local legislation ) Chronic hepatitis C Treatment longacting interferon plus ribavirin Quantifiable HCV RNA initiation treatment No contraindication longacting interferon ribavirin therapy detail label End stage renal disease Major organ transplantation Concomitant therapy telbivudine Pregnant breastfeeding female Male partner pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>